This content is from: Features

How to survive the patent cliff

This year $50 billion worth of drugs come off patent. The pharma industry’s response will be to focus on personalised medicine and biologics. Eileen McDermott explains how this will shift IP strategy towards trade secrets, data and patenting processes

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial

Related